Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
24 Aug 2006 07:00 AM
PRN
Collaboration Agreement
09 Aug 2006 08:03 AM
PRN
Supplementary consideration shares
08 Aug 2006 08:00 AM
PRN
First Day of Dealings
07 Aug 2006 12:58 PM
RNS
Result of EGM
14 Jul 2006 02:20 PM
RNS
Final Results
14 Jul 2006 12:00 PM
RNS
Propsd Aqstn & notice of EGM
13 Jul 2006 09:30 AM
RNS
Stmnt re Proposed Transaction
07 Jul 2006 04:07 PM
RNS
Directorate Change
05 May 2006 11:24 AM
RNS
Result of EGM
19 Apr 2006 03:13 PM
RNS
Further re Issue of Equity
19 Apr 2006 08:08 AM
RNS
Holding(s) in Company
13 Apr 2006 05:28 PM
RNS
Holding(s) in Company
12 Apr 2006 07:44 AM
RNS
Issue of Equity
09 Mar 2006 02:19 PM
RNS
Holding(s) in Company
26 Jan 2006 08:23 AM
RNS
Interim Results
24 Aug 2005 07:00 AM
RNS
Final Results
25 Jul 2005 07:57 AM
RNS
Board change & trading update
17 Jun 2005 11:09 AM
RNS
Business Strategy
25 May 2005 04:55 PM
RNS
Issue of Equity
11 Apr 2005 11:00 AM
RNS
EGM Statement
23 Mar 2005 09:22 AM
RNS
Issue of Equity
15 Mar 2005 03:32 PM
RNS
Notice of EGM
28 Jan 2005 04:48 PM
RNS
Interim Results
25 Oct 2004 11:27 AM
RNS
Holding(s) in Company
30 Sep 2004 02:11 PM
RNS
Director Shareholding
29 Sep 2004 09:08 AM
RNS
Annual Report and Accounts
23 Jun 2004 03:52 PM
RNS
Holding(s) in Company
29 Jan 2004 05:39 PM
RNS
Interim Results
09 Sep 2003 04:25 PM
RNS
Holding(s) in Company
08 Sep 2003 07:00 AM
RNS
First day dealings

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100